Last reviewed · How we verify

Sham Avastin Intravitreal Injection — Competitive Intelligence Brief

Sham Avastin Intravitreal Injection (Sham Avastin Intravitreal Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Ophthalmology.

phase 3 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Sham Avastin Intravitreal Injection (Sham Avastin Intravitreal Injection) — Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. This is a sham (placebo) intravitreal injection used as a control in clinical trials, containing no active pharmaceutical ingredient.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sham Avastin Intravitreal Injection TARGET Sham Avastin Intravitreal Injection Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sham Avastin Intravitreal Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/sham-avastin-intravitreal-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: